Table 1.
Baseline characteristics
| Characteristic | AVATAR protocol arm | Anti-arrhythmic arm | Conventional ablation arm | |
|---|---|---|---|---|
| (n = 110) | (n = 103) | (n = 108) | ||
| Age | Mean (SD) | 60.1 (9.00) | 60.5 (10.34) | 59.7 (12.22) |
| Male sex | Number (%) | 64 (58) | 57 (55) | 66 (61) |
| Body mass index | Mean (SD) | 29.1 (5.04) | 28.0 (4.83) | 28.9 (4.67) |
| Hypertension | Number (%) | 38 (35) | 36 (35) | 29 (27) |
| Diabetes mellitus | Number (%) | 4 (4) | 6 (6) | 4 (4) |
| Sleep apnoea | Number (%) | 1 (1) | 3 (3) | 0 |
| Coronary heart disease | Number (%) | 3 (3) | 3 (3) | 4 (4) |
| CHADSVASC score | 0 | 35 (32) | 36 (35) | 43 (40) |
| 1 | 30 (27) | 24 (23) | 22 (20) | |
| 2 | 28 (26) | 19 (18) | 23 (21) | |
| 3 | 12 (11) | 17 (14) | 10 (9) | |
| 4 | 4 (4) | 4 (4) | 6 (6) | |
| 5 | 0 | 1 (1) | 1 (1) | |
| 6 | 0 | 1 (1) | 2 (2) | |
| Not known | 1 (1) | 1 (1) | 1 (1) | |
| Left ventricular function (ejection fraction) | Mean (SD) | 57.1 (4.88) | 57.9 (5.60) | 58.3 (5.00) |
| Anti-coagulation at enrolment | All agents (%) | 81 (74) | 65 (63) | 76 (70) |
| Warfarin | 13 (12) | 14 (14) | 22 (20) | |
| Apixaban | 30 (27) | 23 (22) | 26 (24) | |
| Rivaroxaban | 30 (27) | 22 (21) | 21 (19) | |
| Dabigatran | 6 (6) | 5 (5) | 4 (4) | |
| Edoxaban | 2 (2) | 1 (1) | 3 (3) | |
AVATAR, Ablation Versus Anti-arrhythmic Therapy for Reducing All Hospital Episodes from Recurrent.